amylin cagrilintide Analogue Boosts Weight Loss When Added to GLP-1 amylin cagrilintide Cagrilintide: Mechanism, Effects

Semaglutide: FDA-approved for weight management (2021) and type 2 diabetes Widely available via prescription Available from research peptide suppliers Established insurance coverage pathways Years of post-marketing safety data Cagrilintide: Not FDA-approved (investigational as of March 2026) Phase 3 REDEFINE trials complete with positive results Available from some research peptide suppliers as a research chemical No insurance coverage Limited long-term safety data (68 weeks maximum from trials) Cost Considerations Without FDA approval, cagrilintide has no established retail price

Research vendors sell the raw compound for laboratory work, so a research vial costs far less

Every milliliter of solution contains 2.5 mg of peptide

The 28.7% average weight loss at 68 weeks surpasses anything else in the pipeline